10-Q: Seres Therapeutics Reports Q1 2025 Results, Highlights SER-155 Development and Partnership Efforts

Seres Therapeutics reports a net income of $32.7 million for Q1 2025, driven by the sale of its VOWST business, while focusing on the development of SER-155 and seeking strategic partnerships.

Summary

• Seres Therapeutics, a clinical-stage company, reported a net income of $32.7 million for the three months ended March 31, 2025, compared to a net loss of $40.1 million for the same period in 2024.
• The company's Q1 2025 performance was significantly influenced by a $52.2 million gain on the sale of its VOWST business to Nestl Health Science.
• Research and development expenses decreased to $11.8 million from $19.5 million year-over-year, reflecting the completion of the SER-155 Phase 1b study and reduced personnel costs.
• General and administrative expenses also decreased to $11.9 million from $14.9 million year-over-year, primarily due to lower personnel-related costs.
• As of March 31, 2025, Seres had cash and cash equivalents of $58.8 million.
• The company anticipates needing additional funding in the first quarter of 2026 to support ongoing operations.
• Seres is progressing the development of SER-155, an investigational live biotherapeutic, and is actively seeking a partner to support its clinical advancement.
• A Phase 2 study for SER-155 is expected to target 248 participants and incorporate an adaptive design with interim results expected within twelve months of study initiation.
• The FDA has granted Breakthrough Therapy designation to SER-155 for the reduction of bacterial bloodstream infections in patients undergoing allo-HSCT.
• The company is also developing SER-147, another live biotherapeutic, designed to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease.

Sentiment

Score: 6

Explanation: The sentiment is cautiously optimistic. The company achieved profitability due to the VOWST sale and is progressing SER-155, but faces financial uncertainties and requires additional funding.

Positives

• The sale of the VOWST business resulted in a significant gain, improving the company's financial position.
• FDA Breakthrough Therapy designation for SER-155 highlights its potential to address a critical unmet need.
• The planned Phase 2 study for SER-155 has a clear timeline for interim results, facilitating timely engagement with the FDA.
• The company is actively seeking a partner to support SER-155 development, potentially mitigating financial risks.
• Exploratory biomarker data from the SER-155 Phase 1b study supports the intended therapeutic mechanisms.
• The company regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split.

Negatives

• The company anticipates needing additional funding in the first quarter of 2026, raising concerns about long-term financial sustainability.
• The receipt of the Second Installment Payment and Milestone Payments from the VOWST sale is subject to various risks and uncertainties.
• The company is a smaller, less diversified company after the sale of VOWST, making it more susceptible to market fluctuations.
• There is substantial doubt about the company's ability to continue as a going concern for 12 months from the date the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, are issued.

Risks

• The company's ability to obtain additional funding is uncertain and could impact its ability to advance product development programs.
• The success of SER-155 and other product candidates is subject to the inherent risks of clinical development and regulatory approval.
• Competition from other companies developing similar therapies could impact the market potential of Seres' product candidates.
• The company's reliance on third-party manufacturers and CROs introduces risks related to supply chain disruptions and compliance with regulations.
• The company's intellectual property may not be adequately protected, allowing competitors to develop similar products.
• The company is subject to complex and changing laws and regulations, which exposes it to potential liabilities and increased costs.
• The company's ability to use its net operating loss carryforwards and research and development credits to offset future taxable income or income tax liabilities may be subject to certain limitations.

Future Outlook

Seres Therapeutics plans to focus on progressing the development of SER-155 and advancing its other wholly-owned live biotherapeutic candidates. The company anticipates needing additional funding in the first quarter of 2026 and is actively seeking a partner to support the development of SER-155.

Management Comments

• Management plans to provide for the Company's capital requirements through financing or other strategic transactions, including potential business development transactions, and selling shares under the Company's at the market equity offering.

Industry Context

Seres Therapeutics operates in the competitive biotechnology industry, focusing on live biotherapeutics. The company's focus on SER-155 and strategic partnerships reflects a trend in the industry towards targeted therapies and collaborative development models. The company's approach aligns with the growing interest in microbiome-based therapies and their potential to address various diseases.

Comparison to Industry Standards

• The company's focus on live biotherapeutics places it in a niche segment of the biotechnology industry, with limited direct comparables.
• Companies like Vedanta Biosciences (now merged with Osel), Finch Therapeutics, and 4D pharma are also developing microbiome-based therapies, but their specific approaches and target indications may differ.
• The company's financial performance and cash runway are critical metrics compared to other clinical-stage biotechs, as they determine the ability to fund ongoing research and development.
• The company's ability to secure partnerships and collaborations is also a key factor in assessing its long-term viability and success, similar to other companies in the industry that rely on external funding and expertise.

Management Changes

Corporate Governance

Legal Proceedings

• On August 20, 2024, Vedanta Biosciences, Inc. and The University of Tokyo filed a complaint against us and Nestl S.A., Nestl Health Science S.A., Nestl Health Science US Holdings, Inc. and SPN in the United States District Court for the District of Delaware alleging that the making, sale and use of VOWST infringes on U.S. Patent Nos. 9,433,652, 9,662,381, 9,808,519, 10,555,978, and 11,090,343.

Related Party Transactions

• The company completed the sale of its VOWST Business to SPN on September 30, 2024.
• The company entered into a Transition Services Agreement (TSA) with NESA, an affiliate of SPN.
• SPN purchased 714,285 shares of Seres' common stock at a purchase price of $21.00 per share.

Stakeholder Impact

• Shareholders: The sale of VOWST has improved the company's financial position, but the need for additional funding and the risks associated with SER-155 development create uncertainty.
• Employees: The company has reduced its workforce following the VOWST sale, but is focused on advancing SER-155 and other pipeline programs.
• Patients: The development of SER-155 and SER-147 has the potential to provide new treatment options for medically vulnerable populations.
• Customers: The sale of VOWST has transferred the responsibility for commercialization to Nestl Health Science.
• Suppliers: The company's reliance on third-party manufacturers and CROs creates dependencies that could impact the supply chain.
• Creditors: The company's ability to secure additional funding will impact its ability to meet its financial obligations.

Next Steps

• Submit the Phase 2 protocol for SER-155 to the FDA.
• Actively seek a strategic partner to support the development of SER-155.
• Continue development of SER-147 and other pipeline programs.
• Monitor and manage cash runway to secure additional funding in the first quarter of 2026.

Key Dates

Keywords

SER-155, VOWST, live biotherapeutics, Nestl Health Science, allo-HSCT, bacterial bloodstream infections, FDA, clinical trials, Phase 2 study, partnership, reverse stock split, going concern, financial results, MCRB